Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: PLM033
MIFTS: 62

Pulmonary Embolism

Categories: Cardiovascular diseases, Respiratory diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Pulmonary Embolism

About this section

MalaCards integrated aliases for Pulmonary Embolism:

Name: Pulmonary Embolism 12 29 55 43 3 44 15 63 73
Pulmonary Artery Embolism 12
Pulmonary Embolus 12

Classifications:

MalaCards categories:
Anatomical: Cardiovascular diseases Respiratory diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:9477
MeSH 44 D011655
NCIt 50 C50713
UMLS 73 C0034065
Sources

Summaries for Pulmonary Embolism

About this section
MedlinePlus : 43 A pulmonary embolism is a sudden blockage in a lung artery. The cause is usually a blood clot in the leg called a deep vein thrombosis that breaks loose and travels through the bloodstream to the lung. Pulmonary embolism is a serious condition that can cause Permanent damage to the affected lung Low oxygen levels in your blood Damage to other organs in your body from not getting enough oxygen If a clot is large, or if there are many clots, pulmonary embolism can cause death. Half the people who have pulmonary embolism have no symptoms. If you do have symptoms, they can include shortness of breath, chest pain or coughing up blood. Symptoms of a blood clot include warmth, swelling, pain, tenderness and redness of the leg. The goal of treatment is to break up clots and help keep other clots from forming. NIH: National Heart, Lung, and Blood Institute

MalaCards based summary : Pulmonary Embolism, also known as pulmonary artery embolism, is related to chronic thromboembolic pulmonary hypertension and respiratory failure, and has symptoms including coughing, hemoptysis and snoring. An important gene associated with Pulmonary Embolism is PLAT (Plasminogen Activator, Tissue Type), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Collagen chain trimerization. The drugs Lidocaine and Clopidogrel have been mentioned in the context of this disorder. Affiliated tissues include lung, heart and brain, and related phenotypes are homeostasis/metabolism and cardiovascular system

Disease Ontology : 12 An artery disease characterized by a blockage of the main artery of the lung or one of its branches by a substance that has travelled from elsewhere in the body, e.g. a blood clot.

CDC : 3 Venous thromboembolism (VTE), also known as blood clots, is an underdiagnosed and serious, but preventable medical condition. It is important to know about VTE because it can happen to anybody at any age and cause serious illness, disability, and in some cases, death. The good news is that VTE can be prevented and treated if discovered early.

PubMed Health : 63 About pulmonary embolism: Pulmonary embolism (PULL-mun-ary EM-bo-lizm), or PE, is a sudden blockage in a lung artery. The blockage usually is caused by a blood clot that travels to the lung from a vein in the leg.A clot that forms in one part of the body and travels in the bloodstream to another part of the body is called an embolus (EM-bo-lus).PE is a serious condition that can:

Wikipedia : 76 Pulmonary embolism (PE) is a blockage of an artery in the lungs by a substance that has moved from... more...

Sources

Related Diseases for Pulmonary Embolism

About this section

Diseases related to Pulmonary Embolism via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 447)
# Related Disease Score Top Affiliating Genes
1 chronic thromboembolic pulmonary hypertension 33.0 CRP F2 NPPB
2 respiratory failure 32.0 ALB CRP F3
3 protein c deficiency 31.1 F2 F5 F9 MTHFR SERPINC1
4 inferior myocardial infarction 31.0 NPPB PLAT
5 patent foramen ovale 30.9 F2 F5 MTHFR SERPINC1
6 inferior vena cava interruption 30.7 F5 MTHFR SERPINE1
7 heparin-induced thrombocytopenia 30.5 F10 F3 SERPINC1
8 pulmonary hypertension 30.4 F3 NPPB PLAT SERPINC1 SERPINE1
9 may-thurner syndrome 30.4 APOH F5
10 sticky platelet syndrome 30.4 F5 SERPINC1 SERPINE1
11 cardiogenic shock 30.2 CRP NPPB PLAT
12 sagittal sinus thrombosis 30.1 F2 F3 F5 SERPINC1
13 coronary thrombosis 30.0 F3 PLAT SERPINC1 SERPINE1
14 acute cor pulmonale 29.9 NPPB PLAT SERPINE1 SERPINF2
15 splenic infarction 29.9 APOH F2
16 kwashiorkor 29.9 ALB F2
17 lemierre's syndrome 29.9 CRP F3 MTHFR SERPINE1
18 thrombocytosis 29.8 CRP F2 F3 SERPINC1
19 varicose veins 29.8 F2 F5 MTHFR SERPINC1
20 atrial fibrillation 29.8 F10 F2 NPPB PLAT
21 cardiac tamponade 29.8 F2 F9 NPPB
22 mediastinitis 29.7 CRP F5
23 thrombophilia due to thrombin defect 29.6 APOH F10 F2 F3 F5 MTHFR
24 afibrinogenemia 29.4 F10 F2 F3 F5
25 peritonitis 29.4 ALB CRP F2
26 hemophilia 29.4 F2 F3 F9
27 pulmonary edema 29.4 CRP F2 NPPB SERPINC1
28 ischemic colitis 29.4 APOH F2 F5 SERPINC1
29 protein s deficiency 29.4 APOH F2 F3 F5 MTHFR SERPINC1
30 von willebrand's disease 29.1 F2 F3 F5 F9
31 tetralogy of fallot 29.1 CRP MTHFR NPPB TNNT2
32 factor xi deficiency 29.0 F2 F3 F9 SERPINC1
33 catastrophic antiphospholipid syndrome 29.0 APOH F3 F5 MTHFR SERPINE1
34 placenta disease 28.9 APOH F3 F5 MTHFR SERPINC1
35 budd-chiari syndrome 28.8 APOH F2 F3 F5 MTHFR SERPINC1
36 buerger disease 28.8 APOH F2 MTHFR PLAU SERPINE1
37 liver cirrhosis 28.7 ALB F2 SERPINC1 SERPINF2
38 infective endocarditis 28.7 APOH CRP F2 SERPINE1 TNNI3
39 antithrombin iii deficiency 28.6 APOH F10 F2 F5 MTHFR SERPINC1
40 vein disease 28.6 ALB F2 F3 F5 MTHFR PLAT
41 factor vii deficiency 28.6 F10 F2 F3 F9
42 purpura 28.5 APOH CRP F2 F3 SERPINC1
43 portal vein thrombosis 28.5 APOH F2 F5 MTHFR SERPINC1 SERPINE1
44 acquired hemophilia 28.4 F10 F3 F5 F9
45 marantic endocarditis 28.4 F2 F3 MTHFR PLAT SERPINC1 SERPINF2
46 hemophilia a 28.4 F10 F3 F5 F9
47 endocarditis 28.1 ALB APOH CRP F2 PLAT SERPINC1
48 dilated cardiomyopathy 28.0 ALB CRP FABP3 NPPB TNNI3 TNNT2
49 thrombophlebitis 28.0 APOH F2 F5 MTHFR PLAT SERPINC1
50 antiphospholipid syndrome 27.9 APOH F10 F2 F3 F5 MTHFR

Graphical network of the top 20 diseases related to Pulmonary Embolism:



Diseases related to Pulmonary Embolism
Sources

Symptoms & Phenotypes for Pulmonary Embolism

About this section

UMLS symptoms related to Pulmonary Embolism:


coughing, hemoptysis, snoring

MGI Mouse Phenotypes related to Pulmonary Embolism:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.16 PLAU F2 SERPINC1 F3 SERPINE1 F5
2 cardiovascular system MP:0005385 10.13 F10 PLAU F2 SERPINC1 F3 SERPINE1
3 mortality/aging MP:0010768 9.83 TNNT2 F10 PLAU F2 SERPINC1 F3
4 liver/biliary system MP:0005370 9.7 PLAU SERPINC1 SERPINE1 F5 F9 FABP3
5 muscle MP:0005369 9.17 TNNT2 PLAU F3 TNNI3 FABP3 ALB
Sources

Drugs & Therapeutics for Pulmonary Embolism

About this section

PubMedHealth treatment related to Pulmonary Embolism: 63

Pulmonary embolism (PE) is treated with medicines, procedures, and other therapies. The main goals of treating PE are to stop the blood clot from getting bigger and keep new clots from forming.Treatment may include medicines to thin the blood and slow its ability to clot. If your symptoms are life threatening, your doctor may give you medicine to quickly dissolve the clot. Rarely, your doctor may use surgery or another procedure to remove the clot.

Drugs for Pulmonary Embolism (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 504)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lidocaine Approved, Vet_approved Phase 4,Not Applicable 137-58-6 3676
2
Clopidogrel Approved Phase 4,Phase 3,Phase 2 120202-66-6, 113665-84-2 60606
3
Furosemide Approved, Vet_approved Phase 4,Phase 3,Not Applicable 54-31-9 3440
4
Warfarin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 81-81-2 6691 54678486
5
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 9005-49-6 772 46507594
6
Phenprocoumon Approved, Investigational Phase 4,Phase 3 435-97-2 9908 54680692
7
Budesonide Approved Phase 4 51333-22-3 63006 5281004
8 fluindione Approved, Investigational Phase 4,Phase 3 957-56-2
9
Aspirin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1 50-78-2 2244
10
Tranexamic Acid Approved Phase 4,Phase 3,Phase 2,Not Applicable 1197-18-8 5526
11
Nitric Oxide Approved Phase 4,Phase 2,Phase 1 10102-43-9 145068 160954
12
Ropivacaine Approved Phase 4,Phase 3,Not Applicable 84057-95-4 71273 175805
13
Ipratropium Approved Phase 4 22254-24-6, 60205-81-4 43232
14
Apixaban Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 503612-47-3 10182969
15 Nadroparin Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 9041-08-1
16
Rivaroxaban Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 366789-02-8
17 Fondaparinux Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1 104993-28-4
18
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1994-09-7, 94-09-7 2337
19
Tinzaparin Approved Phase 4,Phase 2,Phase 3,Not Applicable 9005-49-6, 9041-08-1 25244225
20
Tranylcypromine Approved, Investigational Phase 4,Phase 3 155-09-9 441233
21
Terbutaline Approved Phase 4 23031-25-6 5403
22
Acetylcysteine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 616-91-1 12035
23
Dalteparin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 9005-49-6
24
Thrombin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable
25
Enoxaparin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 9005-49-6 772
26
Fluticasone Approved, Experimental, Investigational Phase 4 90566-53-3 62924
27
Spironolactone Approved Phase 4,Phase 3 1952-01-7, 52-01-7 5833
28
Eplerenone Approved Phase 4,Phase 3 107724-20-9 150310 443872
29
Salicylic acid Approved, Investigational, Vet_approved Phase 4,Phase 3 69-72-7 338
30
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3 22916-47-8 4189
31
Metronidazole Approved Phase 4,Not Applicable 443-48-1 4173
32
Iodine Approved, Investigational Phase 4,Not Applicable 7553-56-2 807
33
Acetaminophen Approved Phase 4,Phase 2,Phase 1 103-90-2 1983
34
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
35
Ibuprofen Approved Phase 4 15687-27-1 3672
36
Acenocoumarol Approved, Investigational Phase 4,Phase 3 152-72-7 9052 54676537
37
Desirudin Approved Phase 4,Phase 2,Phase 3 120993-53-5
38 Edoxaban Approved Phase 4,Phase 3,Phase 2,Not Applicable 480449-70-5
39
Epoprostenol Approved Phase 4 61849-14-7, 35121-78-9 5280427 5282411
40
Streptokinase Approved, Investigational Phase 4 9002-01-1
41
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
42
Pancrelipase Approved, Investigational Phase 4,Phase 3 53608-75-6
43
Polidocanol Approved Phase 4,Not Applicable 9002-92-0
44
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
45
Verapamil Approved Phase 4 52-53-9 2520
46
Bupivacaine Approved, Investigational Phase 4,Phase 1 2180-92-9, 38396-39-3 2474
47
Ketorolac Approved Phase 4,Phase 1 74103-06-3, 66635-83-4 3826
48
Ephedrine Approved Phase 4,Phase 2,Phase 3 299-42-3 9294
49
Pseudoephedrine Approved Phase 4,Phase 2,Phase 3 90-82-4 7028
50
Norepinephrine Approved Phase 4,Phase 2,Phase 3 51-41-2 439260

Interventional clinical trials:

(show top 50) (show all 1130)
# Name Status NCT ID Phase Drugs
1 Home Treatment of Pulmonary Embolism Unknown status NCT00214929 Phase 4
2 Low Dose Rt-PA for Acute Normotensive Pulmonary Embolism With RVD Unknown status NCT01531829 Phase 4 Recombinant tissue plasminogen activator (rt-PA);Low Molecular Weight Heparin
3 Low Dose Prolonged Infusion of Tissue Type Plasminogen Activator Therapy in Massive Pulmonary Embolism Unknown status NCT02029456 Phase 4 25 mg Actilyse ( Boehringer Ingelheim, Germany) infusion in 6 hours
4 Two Weeks of Low Molecular Weight Heparin for Distal Vein Thrombosis Unknown status NCT01252420 Phase 4 Enoxaparin
5 Comparison of Low-Molecular-Weight Heparin (LMWH) and Unfractionated Heparin (UFH) in Combination With Thrombolytic Treatment of Acute Massive Pulmonary Thromboembolism Unknown status NCT01956955 Phase 4 enoxaparin ,alteplase, unfractionated heparin
6 Comparison of Topical and Infusion Tranexamic Acid After Total Knee Arthroplasty Unknown status NCT02453802 Phase 4 Tranexamic Acid 5%,5ml/amp;Tranexamic Acid 5%,5ml/amp;rivaroxaban (10mg);0.9% Normal Saline;0.9% Normal Saline
7 Vascular CalcIfiCation and sTiffness Induced by ORal antIcoAgulation Unknown status NCT02161965 Phase 4 Rivaroxaban;Fluindione;Warfarin
8 Residual Vein Thrombosis and the Optimal Duration of Low Molecular Weight Heparin in Cancer Patients With Deep Vein Thrombosis Unknown status NCT00450645 Phase 4 low molecular weight heparin
9 Applying Pharmacogenetics to Warfarin Dosing in Chinese Patients Unknown status NCT01610141 Phase 4
10 Exhaled NO Based Treatment of Chronic Obstructive Pulmonary Disease (COPD), ICS/LABA Versus LAMA Unknown status NCT02546349 Phase 4 fluticasone/salmeterol, tiotropium
11 Efficacy of Nebulized Pulmicort Respules in Primary Lung Cancer Patients With COPD Unknown status NCT02504801 Phase 4 Budesonide
12 A Safety and Efficacy Study for Implantation and Retrieval Procedures Using the VENATECH® Retrieval Filter System Unknown status NCT02674672 Phase 4
13 Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study Unknown status NCT02642419 Phase 4 Rivaroxaban and single antiplatelet drug (aspirin, clopidogrel or prasugrel);Rivaroxaban
14 Reinflation After Early Tourniquet Release in Total Knee Arthroplasty Unknown status NCT01832272 Phase 4
15 Tranexamic Acid in Knee Joint Surgery Unknown status NCT02278263 Phase 4 Tranexamic Acid;Normal saline (0.9% NaCl)
16 Tranexamic Acid in Intertrochanteric and Subtrochanteric Femur Fractures Unknown status NCT02580227 Phase 4 Tranexamic Acid
17 Comparison of Thrombgolytic and Anticoagulation Therapy in Submassive Pulmonary Embolism Completed NCT02132689 Phase 4 Actilyse (Thrombolytic therapy);Heparine (Standard anticoagulation therapy)
18 A Study of Rivaroxaban for Early Discharge of Low Risk Pulmonary Embolism From the Emergency Department Completed NCT02584660 Phase 4 Rivaroxaban;Standard-of-care
19 Tinzaparin in the Treatment of the Acute Pulmonary Embolism Completed NCT00711308 Phase 4 tinzaparin;acenocoumarol
20 Age-adjusted D-dimer Cut-off Levels to Rule Out Pulmonary Embolism Completed NCT01134068 Phase 4
21 Post-marketing Study of Monteplase ("Cleactor") in Patients With Acute Pulmonary Embolism Completed NCT00442234 Phase 4 Monteplase
22 Deferment of Imaging for Pulmonary Embolism Completed NCT00381511 Phase 4 low molecular weight heparin
23 Recombinant Streptokinase Versus Urokinase in Pulmonary Embolism in China (RESUPEC) Completed NCT00968929 Phase 4 Recombinant Streptokinase;Urokinase
24 PREPIC 2 : Prevention of Recurrent Pulmonary Embolism by Vena Cava Interruption Completed NCT00457158 Phase 4
25 Epoprostenol in Pulmonary Embolism Completed NCT01014156 Phase 4 epoprostenol
26 Protection From Pulmonary Embolism With the Permanent OptEaseâ„¢ Filter (PROOF) Completed NCT00233740 Phase 4
27 Detection of Pulmonary Embolism With CECT Completed NCT00351754 Phase 4 Isovue
28 NAC, NaHCO3 and NS Prophylaxis for CTPA in the ED on Suspicion of PE: A Randomized Controlled Trial Completed NCT02483143 Phase 4 NAC;NaHCO3;Normal Saline
29 3 Months' Versus 6 Months' Anticoagulation in Patients With DVT and/or PE Completed NCT00365950 Phase 4 Duration of anticoagulation;Warfarin duration
30 Venous Thromboembolic Prophylaxis After Trauma: Three Times a Day Unfractionated Heparin Versus Twice a Day Enoxaparin Completed NCT01729559 Phase 4 5000 Units unfractionated Heparin Q 8 hr;30mg enoxaparin Q12 hr
31 Comprehensive Cardiothoracic Dual Source CT for the Early Triage of Patients With Acute Chest Pain Completed NCT01067456 Phase 4
32 D-dimer to Establish Duration of Anticoagulation After Venous Thromboembolism Completed NCT00264277 Phase 4 Vitamin K antagonist (Coumarin anticoagulants)
33 The D-KAF (Dalteparin in Knee-to-Ankle Fracture) Trial Completed NCT00187408 Phase 4 Low Molecular Weight Heparin (dalteparin)
34 Study of IVC Filter Retrieval With the Günther Tulip Vena Cava Filter Completed NCT00196118 Phase 4
35 The Blood Saving Effect of Tranexamic Acid in Total Knee Arthroplasty With Rivaroxaban as Thromboprophylaxis Completed NCT02458729 Phase 4 Tranexamic Acid 5%,5ml/amp (intraoperative);Tranexamic Acid 5%,5ml/amp (3 hours after operation);0.9% Normal Saline (intraoperative);0.9% Normal Saline (3 hours after operation);rivaroxaban (10mg)
36 Rivaroxaban for the Prevention of Venous Thromboembolism in Asian Patients With Cancer Completed NCT01989845 Phase 4 Rivaroxaban
37 Efficacy of Low Molecular Weight Heparin in Superficial Vein Thrombosis Completed NCT01245998 Phase 4 Dalteparin;Dalteparin
38 12-h and 2-h Urokinase Regimes of Pulmonary Thromboembolism in China Completed NCT00799968 Phase 4 Urokinase;Urokinase
39 Low Dosage of rt-PA in the Treatment of Pulmonary Thromboembolism in China Completed NCT00781378 Phase 4 rt-PA;rt-PA
40 The ENIGMA II Trial:Nitrous Oxide Anaesthesia and Cardiac Morbidity After Major Surgery: a Randomised Controlled Trial Completed NCT00430989 Phase 4 Nitrous Oxide;Nitrous Oxide
41 Comparison of Warfarin Dosing Using Decision Model Versus Pharmacogenetic Algorithm Completed NCT00511173 Phase 4
42 PREVAIL: PREvention of VTE After Acute Ischemic Stroke With LMWH Enoxaparin ( - VTE: Venous Thromboembolism - LMWH: Low Molecular Weight Heparin) Completed NCT00077805 Phase 4 Enoxaparin sodium
43 Study to Find Out the Appropriate Initial Dose of the Anticoagulant Drug Phenprocoumon Completed NCT00586287 Phase 4 Phenprocoumon
44 Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients Completed NCT00966277 Phase 4 Dalteparin
45 Nadroparin for the Initial Treatment of Pulmonary Thromboembolism Completed NCT00796692 Phase 4 Nadroparin;Unfractionated heparin(UFH)
46 Pharmacodynamic Drug Interaction Between Warfarin and Amoxicillin-clavulanic Acid Completed NCT00603317 Phase 4 Firstly : Amoxicillin-Clavulanic acid and secondly : Placebo;Firstly : Placebo and secondly : Amoxicillin-Clavulanic acid
47 Safety of Low Dose IV Contrast CT Scanning in Chronic Kidney Disease Completed NCT02476526 Phase 4 Low Volume iso-osmolar non-ionic radio contrast medium;Acetylcysteine Inhalation;Sodium Bicarbonate Solution
48 Tranexamic Acid in Urologic Surgery Completed NCT00670345 Phase 4 Tranexamic Acid;Placebo
49 Cancer Venous Thromboembolism (VTE) Completed NCT02073682 Phase 4 Edoxaban;Dalteparin
50 Efficacy on Pain Following a Procedure for Injecting Sclerotherapeutic Foam Into the Great Saphenous Vein Completed NCT01368159 Phase 4

Search NIH Clinical Center for Pulmonary Embolism

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: pulmonary embolism

Sources

Genetic Tests for Pulmonary Embolism

About this section

Genetic tests related to Pulmonary Embolism:

# Genetic test Affiliating Genes
1 Pulmonary Embolism 29
Sources

Anatomical Context for Pulmonary Embolism

About this section

MalaCards organs/tissues related to Pulmonary Embolism:

41
Lung, Heart, Brain, Testes, Kidney, Prostate, Colon
Sources

Publications for Pulmonary Embolism

About this section

Articles related to Pulmonary Embolism:

(show top 50) (show all 1339)
# Title Authors Year
1
Management of cardiac tamponade during catheter-directed thrombolysis of saddle pulmonary embolism: A clinical dilemma. ( 29970775 )
2018
2
Profile of pulmonary embolism in service personnel posted at high altitude area. ( 29961462 )
2018
3
Design and rationale for the Japanese Registry of Rivaroxaban Effectiveness & Safety for the Prevention of Recurrence in Patients with Deep Vein Thrombosis and Pulmonary Embolism (J'xactly) study. ( 29934383 )
2018
4
Managing pulmonary embolism secondary to suppurative deep vein thrombophlebitis due to community-acquired <i>Staphylococcus aureus</i> in a resource-poor setting. ( 29943741 )
2018
5
Right-sided infective mural endocarditis complicated by septic pulmonary embolism and cardiac tamponade caused by MSSA. ( 29803298 )
2018
6
Pulmonary embolism and infarction with a paradoxical thrombus visualised in both atria. ( 29848540 )
2018
7
Prevalence of Pulmonary Embolism in Patients With Syncope. ( 29379959 )
2018
8
An unusual presentation of pulmonary embolism leading to infarction, cavitation, abscess formation and bronchopleural fistulation. ( 29437738 )
2018
9
Lesson of the month 2: Pulmonary embolism in a patient on rivaroxaban and concurrent carbamazepine. ( 29436450 )
2018
10
Utility of a Clinical Prediction Rule to Exclude Pulmonary Embolism Among Low-Risk Emergency Department Patients: Reason to PERC Up. ( 29450510 )
2018
11
Society of Interventional Radiology Position Statement on Catheter-Directed Therapy for Acute Pulmonary Embolism. ( 29422427 )
2018
12
Mesoaortic compression of a left-sided inferior vena-cava presenting as recurrent pulmonary embolism in a child-a novel anatomic thrombophilia? ( 29350462 )
2018
13
Pulmonary Embolism Among Patients With Acute Exacerbation Of Chronic Obstructive Pulmonary Disease: Implications For Emergency Medicine. ( 29945817 )
2018
14
A new method of CT for the cardiac measurement: correlation of computed tomography measured cardiac parameters and pulmonary obstruction index to assess cardiac morphological changes in acute pulmonary embolism patients. ( 29417409 )
2018
15
A case of Horner's syndrome after catheter-based fibrinolysis for pulmonary embolism. ( 29775165 )
2018
16
Ultrasound-Assisted Catheter-Directed Thrombolysis for Submassive Pulmonary Embolism. ( 29436310 )
2018
17
Half-Dose Versus Full-Dose Alteplase for Treatment of Pulmonary Embolism. ( 29979222 )
2018
18
Phlegmasia cerulea dolens presenting with acute compartment syndrome and pulmonary embolism. ( 29898911 )
2018
19
Acute Massive and Submassive Pulmonary Embolism: Preliminary Validation of Aspiration Mechanical Thrombectomy in Patients with Contraindications to Thrombolysis. ( 29980817 )
2018
20
Imaging for Pulmonary Embolism in Sickle Cell Disease: a 17-Year Experience. ( 29419477 )
2018
21
What's new in severe pulmonary embolism? ( 29947886 )
2018
22
Incidental pulmonary embolism in suspected stroke patients undergoing carotid CT angiography. ( 29426964 )
2018
23
Symptomatic bilateral pulmonary embolism without deep venous thrombosis in an adolescent following arthroscopic anterior cruciate ligament reconstruction: a case report and review of the literature. ( 29976241 )
2018
24
Computed tomography pulmonary angiography is overused to diagnose pulmonary embolism in the emergency department of academic community hospital. ( 29441158 )
2018
25
A Clinically Meaningful Interpretation of the Prospective Investigation of Pulmonary Embolism Diagnosis (PIOPED) II and III Data. ( 29337091 )
2018
26
Optimizing Pulmonary Embolism Computed Tomography in the Age of Individualized Medicine: A Prospective Clinical Study. ( 29438139 )
2018
27
Recognition of unprovoked (idiopathic) pulmonary embolism-Prospective observational study. ( 29414454 )
2018
28
Clinical value of cardiac color ultrasound and cardiac troponin T combined with dynamic electrocardiogram in treatment of acute pulmonary embolism. ( 29434803 )
2018
29
Missed Massive Pulmonary Embolism and the Hidden Threat of a Distal Deep Vein Thrombosis. ( 29435465 )
2018
30
Bilateral pulmonary embolism after arthroscopic anterior cruciate ligament reconstruction: A case report. ( 29966950 )
2018
31
An enigmatic case presentation of Budd-Chiari syndrome with pulmonary embolism: An unusual syndrome with an uncommon complication. ( 29775966 )
2018
32
May-Thurner syndrome and the risk of pulmonary embolism in patients with acute deep venous thrombosis. ( 29909851 )
2018
33
Effect of the Pulmonary Embolism Rule-Out Criteria on Subsequent Thromboembolic Events Among Low-Risk Emergency Department Patients: The PROPER Randomized Clinical Trial. ( 29450523 )
2018
34
Outcomes of Pulmonary Embolectomy for Acute Pulmonary Embolism. ( 29952349 )
2018
35
The YEARS algorithm for suspected pulmonary embolism:shorter visit time and reduced costs at the Emergency department. ( 29431911 )
2018
36
Prognostic assessment for patients with cancer and incidental pulmonary embolism. ( 29445314 )
2018
37
Alcohol Consumption and the Risk of Incident Pulmonary Embolism in U.S. Women and Men. ( 29974610 )
2018
38
British Thoracic Society Guideline for the initial outpatient management of pulmonary embolism. ( 29955362 )
2018
39
Direct oral anticoagulant therapy as an alternative to surgery for the treatment of a patient with a floating thrombus in the ascending aorta and pulmonary embolism. ( 29942913 )
2018
40
Factor Xa inhibition and sPESI failure in intermediate-high-risk pulmonary embolism. ( 29958743 )
2018
41
Electrocardiographic changes in pulmonary embolism: Each lead could be a clue in solving the puzzle. ( 29933149 )
2018
42
Severe pulmonary embolism was secondary to cement inferior vena cava embolism after percutaneous vertebroplasty. ( 29428532 )
2018
43
Recurrent pulmonary embolism associated with deep venous thrombosis diagnosed as protein s deficiency owing to a novel mutation in PROS1: A case report. ( 29742732 )
2018
44
Deep venous thrombosis, pulmonary embolism and long-distance flights. ( 29948593 )
2018
45
Overuse and underuse of pulmonary CT angiography in patients with suspected pulmonary embolism. ( 29977871 )
2018
46
Therapeutic Anticoagulation for Pulmonary Embolism during First Trimester Surgical Abortion: Two Case Reports. ( 29428851 )
2018
47
Cement pulmonary embolism as a complication of percutaneous vertebroplasty in cancer patients. ( 29422089 )
2018
48
Erratum: Acute Pulmonary Embolism: Focus on the Clinical Picture. ( 29968441 )
2018
49
Lung function, functional capacity, and respiratory symptoms at discharge from hospital in patients with acute pulmonary embolism: A cross-sectional study. ( 28937837 )
2017
50
Whole Exome Sequencing Reveals Severe Thrombophilia in Acute Unprovoked Idiopathic Fatal Pulmonary Embolism. ( 28174134 )
2017
Sources

Variations for Pulmonary Embolism

About this section
Sources

Expression for Pulmonary Embolism

About this section
Search GEO for disease gene expression data for Pulmonary Embolism.
Sources

Pathways for Pulmonary Embolism

About this section

Pathways related to Pulmonary Embolism according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Response to elevated platelet cytosolic Ca2+ 66
Show member pathways
 13.01 ALB APOH F10 F2 F3 F5
2
Collagen chain trimerization 66
Show member pathways
 12.6 F10 F2 F3 F5 F9 SERPINC1
3
Folate Metabolism 1
Show member pathways
 12.13 ALB CRP F2 MTHFR PLAT SERPINE1
4
Complement and coagulation cascades 1 37
11.8 F10 F2 F3 F5 F9 PLAT
5
Gamma carboxylation, hypusine formation and arylsulfatase activation 66
Show member pathways
 11.69 F10 F2 F9
6
Senescence and Autophagy in Cancer 1
11.66 PLAT PLAU SERPINE1
7
Formation of Fibrin Clot (Clotting Cascade) 66
Show member pathways
 11.52 F10 F2 F3 F5 F9 PLAT
8
Cell adhesion_ECM remodeling 22
11.39 PLAT PLAU SERPINE1
9
Warfarin Pathway, Pharmacodynamics 61
10.72 F10 F2 F9
10
Dissolution of Fibrin Clot 66
10.67 PLAT PLAU SERPINE1 SERPINF2
Sources

GO Terms for Pulmonary Embolism

About this section

Cellular components related to Pulmonary Embolism according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.93 ALB APOH CRP F2 F3 F9
2 cell surface GO:0009986 9.92 APOH F3 PLAT PLAU SERPINF2
3 extracellular matrix GO:0031012 9.8 APOH F3 PLAT SERPINE1
4 extracellular region GO:0005576 9.8 ALB APOH CRP F10 F2 F3
5 blood microparticle GO:0072562 9.73 ALB F2 SERPINC1 SERPINF2
6 endoplasmic reticulum lumen GO:0005788 9.73 ALB F10 F2 F5 F9 SERPINC1
7 Golgi lumen GO:0005796 9.69 F10 F2 F9
8 platelet alpha granule lumen GO:0031093 9.62 ALB F5 SERPINE1 SERPINF2
9 troponin complex GO:0005861 9.48 TNNI3 TNNT2
10 extracellular space GO:0005615 9.47 ALB APOH CRP F2 F3 F5</